Epstein-Barr virus serology in the chronic fatigue syndrome.
Woodward, C G, Cox, R A · The Journal of infection · 1992 · DOI
Quick Summary
Researchers tested blood samples from 136 ME/CFS patients to look for signs of past or ongoing Epstein-Barr virus (EBV) infection, comparing them to healthy blood donors. They found that CFS patients had higher levels of certain EBV antibodies than the control group, but these differences weren't consistent enough to be useful for diagnosing individual patients. The study also found that some patients had signs of other viral infections alongside the EBV markers.
Why It Matters
This study investigates whether EBV reactivation or persistent infection plays a role in ME/CFS pathogenesis, which remains an important question given anecdotal patient reports of symptom onset following EBV infection. The finding of elevated EBV antibodies in the group suggests viral immune dysregulation may be relevant to ME/CFS, though the lack of individual diagnostic utility indicates EBV serology alone cannot define the condition.
Observed Findings
ME/CFS patients demonstrated significantly higher titres of antibodies to EBV Early Antigen (both Restricted and Diffuse components) compared to blood donor controls (P<0.001)
Elevated EA antibody titres were not useful for individual patient diagnosis or risk stratification
Patients with elevated EA antibodies showed no distinguishing clinical features compared to those with control-range titres
Four of nine patients (44%) with elevated EA antibodies also had serological evidence of active enterovirus infection
Antibody profiles varied widely among the 136 CFS patients studied
Inferred Conclusions
EBV immune dysregulation may be associated with ME/CFS at the group level, suggesting possible viral reactivation or persistent infection in some patients
EBV serology cannot serve as a standalone diagnostic marker for individual ME/CFS patients
Some ME/CFS patients may experience concurrent or sequential infections with multiple viruses, including EBV and enteroviruses
Remaining Questions
Is elevated EBV antibody titre a cause, consequence, or bystander finding in ME/CFS pathogenesis?
Do EBV antibody levels change longitudinally with disease course or treatment interventions?
What This Study Does Not Prove
This study does not prove that EBV causes ME/CFS or that EBV reactivation is necessary for disease development. The elevated group-level antibody titres do not establish active viral replication, and the lack of clinical differentiation between patients with high versus normal titres suggests EBV antibody levels alone do not determine symptom severity or disease course. Cross-sectional design prevents determination of whether elevated antibodies precede or follow symptom onset.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →